Researchers from Affinia Therapeutics Inc. have described the development and preclinical evaluation of a new AAV-based gene therapy, designed using a novel cardiotropic capsid, for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy (HCM).
Researchers from the University of Maryland in collaboration with the National Institutes of Health (NIH) and Duke University have identified angiopoietin-2 (Ang2) as a targetable protein to reverse cardiovascular dysfunction in Hutchinson-Gilford progeria syndrome (HGPS).
Increasing evidence exists regarding the involvement of methyltransferase 1, tRNA methylguanosine (METTL1) in cardiac repair and fibrosis. The search for new therapeutic targets for alleviating ischemic heart disease due to cardiac ischemia/reperfusion injury (IRI) is of vital importance.
Cardiovascular disease is among the leading causes of death in individuals with type 2 diabetes. The role that microRNA 210 (miR-210) plays in endothelial cells and in diabetes-driven endothelial dysfunction is not clearly understood. Its potential as a therapeutic target was investigated.
Among the mechanisms causing calcific aortic valve disease (CAVD) are mitochondrial dysfunction and immune cell infiltration, but it is not well understood just how they impact CAVD pathogenesis.
Isomab Ltd. has nominated ISM-001 as a development candidate for peripheral arterial disease. ISM-001 is a potential first-in-class therapeutic antibody designed to neutralize VEGF-A165b, the anti-angiogenic VEGF-A splice isoform that acts as a brake on development of new blood vessels leading to chronic limb threatening ischemia.
Clinical research has shown that patients with systemic lupus erythematosus (SLE) are more likely to develop cardiovascular disease (CVD), including cardiac and vascular dysfunction. In the current study, researchers from Medical University of South Carolina developed and characterized a novel preclinical model of SLE-like CVD.
CSPC Pharmaceutical Group Ltd. has entered into an exclusive license agreement with Astrazeneca plc for the global development, manufacture and commercialization of CSPC’s lipoprotein(a) (Lp[a]) inhibitor, YS-2302018, and any pharmaceutical or biological product subsequently developed that includes the compound.
Repair Biotechnologies Inc. and Genevant Sciences Corp. have entered into a collaboration and nonexclusive license agreement to combine Repair’s Cholesterol Degrading Platform (CDP) mRNA technology with Genevant’s proprietary lipid nanoparticle (LNP) technology in the development of a potential novel treatment for atherosclerosis.
Scientists from the Cardiovascular Research Center at the University of Virginia School of Medicine and Astrazeneca plc have developed a new mouse model of cardiovascular disease associated with genetic variations of cholesterol metabolism. The animal allows in vivo studies of myocardial infarction, plaque rupture and stroke.